TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Vitrafy Life Sciences Ltd. ( (AU:VFY) ) has shared an update.
Vitrafy Life Sciences Limited announced significant changes in its board during its 2025 Annual General Meeting, with Dr. Leigh Farrell joining as a director and potentially becoming the new Chair, while Dr. John McBain retires. The company is also seeking a new Non-Executive Director to enhance its commercialization efforts. The meeting highlighted the company’s growth and execution in FY25, focusing on animal and human health applications, and included a live demonstration of its advanced cryopreservation technology.
The most recent analyst rating on (AU:VFY) stock is a Buy with a A$2.10 price target. To see the full list of analyst forecasts on Vitrafy Life Sciences Ltd. stock, see the AU:VFY Stock Forecast page.
More about Vitrafy Life Sciences Ltd.
Vitrafy Life Sciences Limited is a company specializing in cryopreservation technology, which significantly enhances cell survival rates for various applications such as blood platelets, cell and gene therapies, aquaculture, and bovine reproduction. The company offers comprehensive cryopreservation solutions through a managed service revenue model, utilizing FDA-registered Smart Freezing and Smart Thawing devices, an integrated LifeChain™ software platform, and Smart Packaging systems.
Average Trading Volume: 25,959
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$97.05M
See more data about VFY stock on TipRanks’ Stock Analysis page.